Of the cardiometabolic interventions the wiki holds, BP-lowering is the one whose hard-outcome benefit is proven to reach primary prevention — the partial exception to Cardiometabolic Interventions and Hard CV Outcomes in Low-Risk People. The largest randomised evidence base (BPLTTC 2021, «344 716 participants from 48 randomised clinical trials») settles two long- contested questions: the benefit does not require pre-existing heart disease, and it does not vanish at lower baseline blood pressure.
The effect, and why its independence from baseline is the point
«a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values».
Per 5 mmHg SBP reduction, the hazard ratio for a major CV event was 0.91 (0.89-0.94) in people without prior CVD and 0.89 (0.86-0.92) in those with it [EXTRACTED (BPLTTC - Blood Pressure Lowering Primary and Secondary Prevention 2021) Results]. Across seven baseline-SBP strata from <120 to >=170 mmHg there was «no reliable evidence of heterogeneity», and «in no subgroup was the HR above 1·0». Component reductions per 5 mmHg: stroke 13%, heart failure 13%, ischaemic heart disease 8%, CV death 5%.
This is what distinguishes BP-lowering from the other cardiometabolic levers. Lifestyle weight loss was null on hard events even where it was achieved (Does Weight Loss Reduce Cardiovascular Events); an obesity drug’s CV benefit is unproven outside established disease (Semaglutide for Cardiovascular Risk in Obesity); a statin’s is real but decays to below the action threshold at low risk (Statins for Primary Prevention and the Power of Zero CAC). BP-lowering alone has a directly proven relative benefit in primary prevention, at an IPD-meta-analytic warrant.
But the ceiling’s mechanism survives — treat on absolute risk, not a BP number
The paper does not conclude lower everyone’s BP. Its explicit decision rule is the Baseline Risk and the Relative-Absolute Split applied to blood pressure:
physicians should «emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself»; the finding «calls for consideration of blood pressure-lowering treatment for any individual who has a sufficiently high absolute risk of cardiovascular disease».
And the guard against over-reading, in the authors’ own words: the uniform relative effect «does not necessarily mean that it is worthwhile treating every patient» — decisions «will require consideration of… an individual’s overall risk of future cardiovascular events, potential risk of adverse effects, the cost of treatment, and patient preferences». They even «caution against using the reported absolute risk differences from clinical trials for making policy decisions» — the trials’ populations were higher-risk (absolute rates «31·9… in the comparator group and 25·9… in the intervention group» per 1000 person-years without prior CVD, i.e. a ~2.4%/yr baseline, far above a low-risk primary-prevention person).
So BP-lowering refines, not refutes, the ceiling. Its relative benefit is proven where weight-loss and GLP-1 CV benefit are not — but the absolute benefit still scales with baseline risk, exactly the ceiling’s mechanism, and the paper legislates the same rule (treat on absolute risk). A constant ~10% per 5 mmHg on a low absolute risk is a small absolute gain; on a high one it is large.
What it does not settle
- Not the target. BPLTTC standardises to a fixed 5 mmHg reduction and shows a consistent relative effect; it «is unable to directly address» the optimal magnitude or a target BP. How low to go is a separate question — now partly held via SPRINT below.
- Not the drug/adverse-effect trade-off for an individual — adverse effects, cost and preferences are named as decision inputs but not quantified — SPRINT supplies the harm side, below.
SPRINT — the intensive-target trial that operationalises treat on absolute risk
BPLTTC is the meta-analysis and carries the per-mmHg claim; SPRINT is one landmark RCT, read inside that framing as the worked target-trial. It randomised 9,361 high-CV-risk, non-diabetic hypertensives to a systolic target «less than 120 mm Hg (intensive)» vs «less than 140 mm Hg (standard)» (achieved ~121 vs ~136), and stopped early (median 3.26 y):
- Intensive won on hard outcomes: primary composite (MI/ACS/stroke/HF/CV-death) «hazard ratio … 0.75; 95% CI 0.64 to 0.89»; and all-cause mortality «hazard ratio, 0.73; 95% CI 0.60 to 0.90» — a 25% and 27% relative reduction, «number needed to treat … to prevent one primary outcome event was 61» over 3.26 years. [EXTRACTED (SPRINT - Intensive vs Standard Blood Pressure 2015) chunk 01]
- It confirms BPLTTC’s own logic rather than competing with it. SPRINT selected a high-risk
population — exactly where BPLTTC says the absolute benefit of a given relative effect is largest —
and the ~15 mmHg achieved gap, at BPLTTC’s ~0.91 per 5 mmHg, predicts a composite HR near 0.75, which
is what SPRINT observed.
[INFERRED — the ~15 mmHg x 0.91/5mmHg ≈ 0.75 arithmetic is the wiki's; and SPRINT is one of the trials inside the BPLTTC pooled estimate, so this is a worked example, not independent confirmation.] - The harm side BPLTTC did not quantify: intensive treatment raised serious «hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not … injurious falls». [EXTRACTED (SPRINT - Intensive vs Standard Blood Pressure 2015) chunk 01] So a lower target buys real events in the high-risk but at a real adverse-event cost — the target decision is a net-effect judgement, not lower is always better.
A clean refutation of the observational J-curve
The intro records the standing controversy: registries show a «J-shaped association» between BP and events (lowest risk ~130/75, implying harm below), which had been read as a reason not to lower BP far. The randomised evidence shows benefit «down to less than 120 mm Hg» with no rising HR in any low-BP stratum — so the observational J-curve is not a treatment effect. A worked instance of The U-Shaped Association Artifact: the protective-looking lower arm of an observational curve does not survive the randomised (here, interventional) check.
Decision relevance
- BP-lowering is the cardiometabolic lever with the best hard-outcome warrant, and it applies in primary prevention — for a hypertensive person it is the one place a proven CV-event reduction is on the table.
- But decide on absolute CV risk, not the BP number. A ~10%-per-5-mmHg relative effect buys little absolute benefit at low risk and a lot at high risk; combine the relative effect with a stratum- specific baseline (SCORE2 Baseline Risk and the ESC Treatment Thresholds) rather than treating to a threshold. This also means the exact BP measurement matters less than the overall risk.
- Lifestyle BP reduction (e.g. sodium, weight) plugs into the same channel. Sodium Intake and Blood Pressure holds BP as a surrogate with hard outcomes graded very low; BPLTTC supplies the missing link — pharmacological BP reduction does reduce hard events — but the transmission of a sodium-induced BP drop to events is an assumption, not the same evidence (a different intervention, unmeasured here).
Limits
- Trials 1972-2013 — older drug regimens and co-treatment; relative (not absolute) effects are the transportable quantity, by the authors’ own caution.
- One (very large) collaboration’s IPD; the target-BP and adverse-effect questions are out of its design.
- Applies to pharmacological lowering; do not silently transfer the magnitude to a lifestyle route.